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Abstract
Background: We have developed a cell-based vaccine that features the expression of both CD80
and CD86 on the surface of a murine neuroblastoma cell line. The cellular immunity induced by
this vaccine is enhanced by treatment with antibody that interferes with T-regulatory cell (Treg)
function and we report here that immunization combined with interfering with Treg function also
produces a profound serological effect. Serum from mice immunized with our cell-based vaccine in
the context of Treg blockade was used to screen a cDNA expression library constructed from the
parental neuroblastoma tumor cell line, AGN2a.
Results: Serum from mice vaccinated in the context of Treg blockade identified a number of
potentially oncogenic transcripts that may serve as important immune targets in a tumor-derived
cDNA library screen. This novel approach identified far more candidates than could be seen with
serum derived from vaccine-treated only, Treg-depleted only, or tumor-bearing mice. The most
commonly identified tumor-associated antigen, using serum from immunized and Treg-depleted
mice, was the DEK oncogene. Altered expression of the DEK oncogene has been implicated in a
number of human cancers. Importantly, we were able to demonstrate that the DEK oncogene also
induces a T cell response.
Conclusion:  The use of post-vaccine immune serum in this report differs from previous
approaches where serum collected at the time of cancer onset or diagnosis and was used for tumor
antigen identification. We hypothesize that the use of diagnostic serum samples may be inadequate
for the clinical translation of this approach, and that identification of protective immunogenic tumor
antigens may require the use of serum from post-treatment or vaccinated subjects. The
identification of DEK as a tumor-associated antigen capable of eliciting a T cell response validates
our experimental approach and argues for the antigens we have identified here to be evaluated as
targets of effector immunity and as vaccine candidates.
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Background
Advanced neuroblastoma poses a grave clinical challenge
and still awaits effective therapy. Early clinical observa-
tions, combined with a slight but demonstrable positive
impact of bone marrow transplantation on outcome has
motivated the development of immune approaches to
therapy [1-4]. In murine models of human neuroblast-
oma, anti-tumor immunity can be generated using cell-
based vaccines where tumor cells have been genetically
modified to express soluble cytokines or cell-surface
immunostimulatory molecules [5-7]. Our own work has
demonstrated that cancer cell-based vaccines expressing
multiple immune co-stimulatory molecules in the murine
neuroblastoma cell line AGN2a can transform this tumor
cell line in to a vaccine that induces strong cell-based
immunity to the unmodified parental cell line [8,9].
Based on the ability to induce an immune response with
cancer cell-based vaccines, human trials with neuroblast-
oma patients have been carried out [10]. Although these
cell-based cancer vaccines did not prove immediately
effective, they were demonstrated to be safe and are ripe
for further optimization [11].
In experimental systems, immunity to neuroblastoma can
be amplified by the blockade of T-regulatory cell (Treg)
function with anti-CD25 antibody (B.D. Johnson, et al.,
2007, J. Immunother., in press). Treg are known to sup-
press the immune response to self-antigens, including
tumor-self antigens, and thwarting this tolerogenic role by
their depletion has become a major focus in the develop-
ment of new immunotherapeutic strategies to treat
human malignancy [12,13]. Golgher et al. have demon-
strated that CD25+ T cell depletion uncovers immune
responses to the tumor cell type used as a vaccine, and
importantly that this response broadens to include other
syngeneic tumor cell types [14]. Given the ability to
induce immune recognition of what are normally consid-
ered "self" antigens upon Treg blockade, we reasoned that
treatment of experimental animals with cell-based cancer
vaccines in the context of anti-CD25 antibody treatment
would induce a strong anti-neuroblastoma immune
response. The proposed use of serology to uncover T cell
antigens is supported by the recent description of anti-
body as well as T cell responses to the DBY minor histo-
compatibility antigen in allogeneic stem cell
transplantation [15,16]. The breaking of tolerance to self-
antigens with Treg depletion may be functionally analo-
gous to the anti-tumor effect seen in allogeneic bone mar-
row transplantation, whose primary side-effect, graft-
versus-host disease, is evidence that tolerance to normal
self antigens has been modified.
The serological analysis of recombinant cDNA expression
libraries (SEREX) constructed from patient tumor was
established by Sahin and Tureci who demonstrated that
this process identifies T-cell antigens as well as B-cell anti-
gens [17,18]. SEREX continues to be employed in patient
studies and has even proven to identify intracellular anti-
gens targeted by the immune system [19]. The identifica-
tion of the NY-ESO-1 antigen in patients by SEREX
demonstrated that both MHC class II restricted epitopes
and MHC class I-restricted (HLA-A2) epitopes, targets of
cytotoxic T cell responses, could be identified with this
technique [19]. We present a new means to identify
immunogenic tumor antigens. In this report we employ
serum from experimental animals that have been vacci-
nated in the context of anti-CD25 antibody treatment, as
opposed to using sera from tumor-bearing animals, which
would be the equivalent of using serum from newly diag-
nosed patients. The use of immune serum-SEREX has
allowed us to identify new tumor-associated antigens in
our neuroblastoma model. Notably, we demonstrate that
one of the antigens identified by our immune-SEREX
approach, the DEK oncoprotein, induces a T cell response
as well as an antibody response. Translation of this con-
cept in to clinical studies would require the used of post-
treatment or even post-vaccination serum, as opposed to
the initial samples commonly harvested at the time of
diagnosis.
Results
The modification of syngeneic tumor cell lines with
immune co-stimulatory molecules can transform lethal
tumor cell lines into effective vaccines. The immunization
of A/J mice with a cell-based vaccine, AGN2a-CD80/
CD86, has been demonstrated to induce a strong cellular
immune response [8]. This immune response is enhanced
when the vaccine is given in the context of anti-CD25 anti-
body (clone PC61) as a means to block and/or deplete T-
regulatory cells. We sought to explore the specificity of the
immunoglobulin response to this cell based vaccine, as a
means to potentially uncover new tumor-associated anti-
gens. To do so, we constructed a cDNA library using
mRNA purified from the AGN2a cell line and expressed
proteins encoded by tumor- derived mRNA in E. coli
using the λZAPII phage system. To identify clones express-
ing antigenic epitopes recognized by IgG present in
immune sera, a total of 2 × 105 clones were screened. Fifty-
eight unique plaques were identified as expressing pro-
teins that could be recognized by IgG antibody when
serum from AGN2a-CD80/CD86+PC61 treated mice was
used at a dilution of 1:250. When pooled serum (n = 5 for
each group) from naïve mice, tumor-bearing mice, mice
treated with PC61 alone, or mice treated with two weekly
injections of the vaccine cell-line AGN2a-CD80/CD86
alone was used to screen the cDNA library 0, 0, 0, or 5
unique clones, respectively, were identified. Antibody-
reactive plaques identified by serum from the AGN2a-
CD80/CD86+PC61-treated mice were picked, used to re-
infect E. coli, and once more serologically screened. ABMC Immunology 2007, 8:4 http://www.biomedcentral.com/1471-2172/8/4
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third round of plaque purification was not required, as it
always resulted in uniform recognition of phage-
expressed proteins. In vivo excision was performed with
helper phage and phagemid DNA isolated. Each
phagemid insert was DNA sequenced using both T7 and
T3 primers, and this sequence was used to search on-line
databases. The 58 clones identified by immune serum-
SEREX screening encoded 25 individual proteins, as listed
in Table 1. Most notable was the frequency with which
DEK was detected. While all antigens listed in Table 1
were detected once from a single positive clone, the DEK
antigen was detected 34 separate times. Careful inspection
of the cDNA library clones demonstrates that most tran-
scripts seem to have some role in neuronal differentiation,
cell cycle control, or have previously been identified as
transcripts that are over-expressed in other malignancies.
The final 4 transcripts listed in Table 1 have no published
or annotated functional analysis associated with them,
beyond their naming and characterization using bioinfor-
matic techniques. Primers were generated for each clone
identified, and expression of each verified by PCR analysis
of AGN2a-derived cDNA (not shown).
To further determine the significance of the SEREX identi-
fied transcripts, we performed cDNA microarray analysis
to examine the expression level of these genes in mouse
neuroblastoma cell lines Neuro-2A and TBJ or in mouse
tissues. A total of 22 out of 25 genes were present in the
array and were used for hierarchical clustering analysis,
Figure 1. Importantly, the majority of the transcripts iden-
tified by SEREX are over-expressed in neuroblastoma cell
lines, indicating the ability of immune serum-based
SEREX analysis to identify over-expressed proteins using
serum from vaccine-treated mice. Of note, DEK is indeed
over-expressed in the neuroblastoma cell lines tested.
The cluster analysis displayed in Figure 1, identifies four
different categories of neuroblastoma antigen expression
profiles. In Cluster 1, transcripts are over-expressed in the
mouse neuroblastoma cell lines in a tumor-restricted
manner: Chgb, Dus31, 2310042G06Rik, Psma6 (proteas-
ome subunit), Csnk2a1 (casein kinase), Mtrr (metabolic
activation), and Hspa8 (heat shock protein). An interest-
ing sub-group within this cluster includes Chgb, chrom-
ogrannin B, which is known to be associated with
sympathetic neurons and which is also found in adrenal
tissue. In Cluster 2 we find transcripts that are overex-
pressed in neurboastoma cells lines as well as spleen or
lung: CD9 (tetraspanin, neuroblastoma marker), Plod3
(collagen biosynthesis), Fusip1 (neuronal differentia-
tion), Brd2 (transcription), Tuba2 (tubulin alpha), DEK,
Prpf38b, Hmgb1 (inflammatory mediator), and Serbp1
(serpine). Some of the proteins in this group, like CD9
and Hmgb1function as immune modulators. Cluster 3
(Crlf3 and Mier 1) and Cluster 4 (Atp5c1, Suv39h1, Immt,
Slca6) are not over-expressed in neuroblastoma cells lines
and seem unlikely to play a role in neuroblastoma. They
may either be cross-reactive antigens or specific targets of
auto-immune responses. We propose that each of the
Cluster 1 and Cluster 2 transcripts should be explored
with regard to tumorigenesis and immunogenicity.
Before we explored the specific immune response to DEK
we sought to demonstrate that the immune response to a
cell-based tumor vaccine is fundamentally altered by
treatment with Treg-depleting antibody. The was first
demonstrated qualitatively, whereupon western blotting
of AGN2a cell lysates with serum from naïve, vaccinated
(AGN2a-CD80/CD86), or vaccinated and Treg-depleted
mice, different protein bands were recognized by the dif-
ferent sera, figure 2. Although prominent bands were seen
with both the vaccine only group (figure 2A, lane 4), these
differed from the prominent bands in the mice vaccinated
in the context of Treg depletion (lane 5). To examine the
differences in the response to a single protein we com-
pared the antibody titer in an ELISA assay using recom-
binant DEK as the target and the same set of sera.
Recombinant DEK protein was produced in the pET15b
bacterial vector encoding an amino-terminal 6-histidine
sequence to facilitate purification on a nickel affinity col-
umn. Enhanced green fluorescent protein (EGFP) was
produced as a negative control. To obtain sufficient pro-
tein for immune function assays pET15b vectors were
used to transform the BL21 (DE3) pLysS E. coli strain,
protein expression induced with IPTG, and proteins con-
taining the 6x-histidine tag purified from bacterial lysates
using a Ni-NTA column. When columns were eluted with
imidazole, distinct bands of 55 kD for DEK and 30 kD for
EGFP were readily resolved by SDS-PAGE and Coomassie
blue staining of the resolved proteins, Figure 3A.
We then tested if purified DEK was recognized by anti-
human DEK antibody and anti 6x-histidine antibody.
Western blot analysis demonstrated that bacterially-
expressed mouse DEK was recognized by anti-human
DEK antibody and that anti-6x-histidine antibody recog-
nized the histidine tag encoded by both recombinant pro-
teins, Figure 3B. Having confirmed that the anti-human
antibody recognized murine DEK, we looked at two cellu-
lar targets for the expression of DEK by immunofluores-
cence (IF). We analyzed both the wild-type/parental
AGN2a cell line and AGN2a transfected with pcDNA3.1-
Hygro/DEK (AGN2a/DEK), in order to induce over-
expression of the DEK oncogene. Both AGN2a and
AGN2a/DEK showed strong nuclear immunoreactivity by
IF, with AGN2a/DEK showing more intense staining, Fig-
ure 4. While the expression of DEK was variable in
AGN2a, strong expression was seen in every AGN2a/DEK
transduced cell, as demonstrated by exact overlap of the
DAPI and DEK signals. To further confirm that the phage-BMC Immunology 2007, 8:4 http://www.biomedcentral.com/1471-2172/8/4
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expressed DEK cDNA was a genuine immune target we
tested serum from tumor-vaccinated mice for the presence
of DEK-reactive immunoglobulin by ELISA. Using poly-
styrene plates coated with recombinant DEK, DEK-reac-
tive IgG could be readily detected in serum from mice
immunized with AGN2a-CD80/86 in the context of PC61
treatment, Figure 5. Anti-human DEK antibody was used
as a positive control antibody in the ELISA. This assay also
supports our hypothesis that vaccination in the context of
Treg depletion alters the nature of the immune response
to cell-based tumor vaccines. High titer DEK antibody
production required the depletion of Treg, while vaccina-
tion with the cell based vaccine, AGN2a-CD80/CD86, did
not produce anti-DEK IgG.
To investigate the CD8+ T cell response against DEK in
mice that had received a cell-based cancer vaccine, A/J
mice were given two weekly subcutaneous (s.c.) injections
of 2 × 106 irradiated AGN2a-CD80/CD86 cells cultured in
DMEM supplemented with 2% mouse serum or 10% FBS,
and Treg activity inhibited by the i.p. injection of clone
PC61 anti-CD25 antibody three days prior to the first vac-
cination. Mouse serum-cultured vaccine cell lines were
used in order to control for potential FBS reactivity, which
has been reported in the analysis of CD4 T cell responses.
AGN2a-CD80/86 was cultured in normal mouse serum at
least two weeks prior to immunization studies. Spleno-
cytes were collected 5 days after the second vaccination,
depleted of RBCs, and CD8+ T cells purified by immu-
nomagnetic selection. T cell responses to DEK were
detected in IFN-γ ELISPOT assays using two different
sources of antigen-presenting cells. In the first assay, peri-
toneal exudate cells (PEC, which are primarily composed
of macrophages) loaded with recombinant DEK protein
Table 1: Neuroblastoma antigens identified by immune serum and SEREX.
Identity of cDNA SEREX hit Accession Characteristics Ref
DEK BC055451 p53 interaction, blocks apoptosis
DNA binding/chromosomal organization,
Proofreading of splicing
Fused to can in leukemia
Wise-Draper '06
Waldman '04
Soares '06
Garcon '05
Hspa8, heat shock protein 8 (Hsc70) NM_031165 Promotes cell-cycle progression (w/cyclin 
D1)
Binds/regulates dbl proto-oncogene
Diehl '03
Kauppinen '05
Fusip1, FUS interacting protein (Nssr, TASR) BC0832082 Neuronal Differentiation, modulates
neuronal mRNA splicing
Over-expressed in liposarcoma and 
leukemia
Liu '04
Fushimi '05
Clinton '02
Hmgb1, high mobility group box-1 BC008565 Inflammatory mediator
DNA binding, architecture regulation
Andreason '02
Stott '06
Atp5c1, ATP synthase (mitochondrial F1 complex, gamma polypeptide 1) BC010700 ATP biosynthesis, upregulated in STI571-
resistant leukemia
Hofmann '02
Sfrs5, splicing factor, arginine/serine-rich (SRp40, HRS) BC085267 Splicing factor, Akt substrate
Apoptosis resistance
Patel '05
Tidd '03
Prpf38b, pre-mRNA processing factor (PRP38) BC050900 snRNP, required for spliceosome activity Xie '98
Tuba1, tubulin, alpha 1 BC085256 Upregulated in carcinoma Qi '05
Chn1, chimerin 1 BC010825 Neurotrophin target Mizuno '04
Csnk2a1, casein kinase II, alpha 1 polypeptide BC060742 Phosphorylates/activates NFkappaB Chantome '04
Mkks, McKusick-Kaufman syndrome protein NM_021527 Chaperonin, required for cytokenesis Kim '05
Mier1, mesoderm induction early response 1 (Mi-er1, er1) AK129405 Fibroblast growth factor induced, 
HDAC1 interaction, transcription factor
Ding '03
Post '05
MTTR, 5-methyltetrahydrofolate-homocysteine methyltransferase reductase BC025942 Mutations seen in neural tube defects
Influences ALL susceptibility
Wilson '99
Gemmati '04
Psma6, proteasome subunit, alpha type 6 NM_011968 Upregulated in hepatocellular ca. Cui '06
CD9 NM_007657 Cell surface tetraspannin, neuronal 
differentiation and neuroblastoma marker
Ishibashi '04
Komada '00
Chromogranin B, Chgb (secretogranin I) NM_007694 Present in neuroblastoma secretory 
vesicles
Goodall '97
Brd2, bromodomain containing 2 (NAT, Rnf3, Ring3, Fsrg1) NM_001025387 Binds to KSHV, LANA-1 protein
Lymphomagenesis
Viejo-Borbolla '05
Greenwald '04
Crlf3, cytokine receptor-like factor 3 AL591113 Upregulated in skin cancer Dang '06
Plod3, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (LH3) NM_011962 Collagen biosynthesis
Upregulated in chemo resistant ca.
Rautavuoma '04
Cleator '05
Immt, inner membrane protein mitochondrial (HMP; P87; P89; P87/89) AK038129 Energy metabolism John '05
Suv39h2, suppressor of variegation 3–9 homolog 2 AF149205 Epigenetic regulation of telomere length Garcia-Cao '04
Serbp1, serpine1 mRNA binding protein BC006030 inferred function (by Gene Ontology)
Dus3l, dihydrouridine synthase 3-like AY040840 inferred function (by Gene Ontology)
Slc9a6, Solute carrier family 9 (Na+/H+ exchanger) AK028350 inferred function (by Gene Ontology)
2310042G06Rik BC026968 Riken cDNA, predicted protein
The table lists the name (identity) of the recombinant plaques in the AGN2a cDNA library that expressed IgG-reactive protein using serum from mice immunized with 
AGN2a-CD80/86 in the context of PC61 treatment three days prior to first vaccine. Each transcript was identified a single time, with the exception of DEK, as detailed in 
Results. The table also lists the accession number, relevant characteristics of the identified protein, and the references that initially reported these functions. All information is 
derived from publicly available databases including Entrez Gene, National Center for Biotechnology Information, National Library of Medicine, U.S. National Institutes of 
Health.BMC Immunology 2007, 8:4 http://www.biomedcentral.com/1471-2172/8/4
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were used. Harvested PEC were plated in ELISPOT plates,
incubated with recombinant DEK or EGFP for 4 hours at
37°C, and then immune CD8+ T cells added to the plates
for an additional 18 hours. Control cultures containing T
cells plus non-protein-loaded PEC, or T cells plus EGFP-
loaded PEC, had similar low numbers of IFN-γ-producing
cells, Figure 6A. In contrast, significant anti-DEK reactivity
was seen in T cells from mice immunized with AGN2a-
CD80/86 and treated with PC61, whether the vaccine cell
line had been cultured in FBS or normal mouse serum
(ms), Figure 6A.
The second source of antigen-presenting cells used to
monitor anti-DEK responses was the AGN2a cell line we
produced that over-expresses DEK (Figure 2). CD8+ T cells
were purified from naïve mice, mice treated only with
Gene Expression of DEK and other Neuroblastoma Tumor-Associated Antigens Identified by Immune Serum-SEREX Figure 1
Gene Expression of DEK and other Neuroblastoma Tumor-Associated Antigens Identified by Immune Serum-SEREX. Expres-
sion of antigens in mouse neuroblastoma cell lines (the parental line for our vaccine, Neuro-2a, and TBJ) and normal mouse tis-
sues are presented as a heatmap. A Total 22 of 25 SEREX identified genes listed in Table 1 are present in the mouse cDNA 
microarray chip and were used for the hierarchical clustering analysis. In the case of multiple clones representing the same 
gene, the average of expression ratios was used (labeled as GeneName_avg). The Pearson correlation matrix was used for 
clustering. Expression level of each gene was log2 transformed and z-score normalization was performed across samples for 
each gene. The expression was represented by pseudo-colors according to the scale shown on the bottom. A red color corre-
sponds to up-regulation and a green color corresponds to down-regulation compared with the mean.
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Western Blot Analysis of Whole Tumor Cell Lysates Figure 2
Western Blot Analysis of Whole Tumor Cell Lysates. (A) AGN2a cell lysate was prepared (as in Methods) and the indicated 
immune serum used at a dilution of 1:100. Lane 1, molecular weight marker (mw); Lane 2, naïve serum; Lane 3, serum from 
PC61-treated mice; Lane 4, serum from AGN2a-CD80/86 immunized mice; Lane 5, serum from AGN2a-CD80/86+PC61 
(Treg-depleted)treated mice. (B) SDS-PAGE analysis showing, Lane 1, mw marker (mw) and, Lane 2, total AGN2a lysate (5 × 
104 cell equivalents/well).
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SDS-PAGE and Western Blot Analysis of Recombinant DEK Figure 3
SDS-PAGE and Western Blot Analysis of Recombinant DEK. (A) Bacterial lysates and Ni-NTA column purified protein were 
diluted in reducing sample loading buffer, resolved by SDS-PAGE and stained with Coomassie blue. Lanes were loaded with 1) 
molecular weight (mw) marker, 2) control bacterial lysate, 10 μl, 3) pET-15b/DEK lysate, 10 μl, 4) 1.5 μg Ni-NTA column-puri-
fied DEK, 5) pET-15b/EGFP lysate, 10 μl, 6) 1.5 μg Ni-NTA column-purified EGFP. (B) Proteins were resolved by SDS-PAGE 
and then transferred to PVDF membrane using a Bis-Tris electrophoresis buffer system for western blot analysis. In blot (a) 
lanes contained: 1) mw marker, 2) control bacterial lysate, 3) pET-15b/DEK lysate, 10 μl, 4) 0.15 μg Ni-NTA column-purified 
DEK, 5) pET-15b/EGFP lysate, 10 μl, 6) 0.15 μg Ni-NTA column-purified EGFP. Blot (a) was probed with anti-6x-His antibody. 
For blot (b) a separate gel containing the same samples loaded in blot (a) was probed with anti-human DEK monoclonal anti-
body. Bound antibody was detected in both blots with alkaline phosphatase (AP)-conjugated rabbit anti-mouse IgG (H+L) sec-
ondary antibody, as described in Methods. Data is representative of more than three separate experiments.
1             2    3     4     5      6
64
39
51
97kD
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28
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PC61 (anti-CD25 antibody), or from mice that received
both the AGN2a-CD80/86 vaccine and PC61. While naïve
or PC61-treated mice did not show any IFN-γ ELISPOT
activity in response to AGN2a, vaccinated mice showed
relatively strong ELISPOT reactivity against both unmodi-
fied AGN2a tumor cells and heightened responses against
the DEK-over-expressing cell line, Figure 6B. Taken
together these assays demonstrate that anti-DEK CD8 T
cell responses are induced by our vaccine+PC61 immuni-
zation protocol. This also validates that our serologic
cDNA screening assay, based on the use of immune serum
rather than tumor-onset serum, can identify important T
cell epitopes.
Discussion
SEREX analysis has been used to identify tumor-associ-
ated antigens in a number of malignancies. Primarily,
patient serum has been used to screen tumor-derived
cDNA libraries. The immunological rationale for the
SEREX approach is that unique tumor antigens should
induce an antibody response. However, the induction of
tolerance to tumor antigens is now recognized to be a for-
midable obstacle to inducing anti-tumor immunity. It
may well be that the antibody specificities present in
tumor-bearing patients or animals represent antigens to
which a tolerized, or non-tumoricidal immune response
has been generated.
During our use of a pre-clinical model to test novel cell-
based vaccines for neuroblastoma, we found that transfec-
tion of the AGN2a cell line with immune co-stimulatory
molecules transforms the immunologically silent tumor
into a powerful locus of immune activation. Moreover,
immunization with a genetically modified tumor cell line,
AGN2a-CD80/86, is even more effective when adminis-
tered in the context of Treg blockade/depletion with an
anti-CD25 mAb, PC61. In using PC61 it is also possible to
deplete activated effectors, as all T cells express CD25
upon stimulation. Although we have not directly explored
effects on antibody production, a single round of PC61
treatment prior to two weekly injections with a cell-based
vaccine is superior to depletion three days prior to each of
Immunofluorescence (IF) Analysis of DEK expression Figure 4
Immunofluorescence (IF) Analysis of DEK expression. AGN2a (column 2) or AGN2a/DEK (columns 1 and 3) were plated on 
glass chamber slides, fixed with 4% paraformaldehyde and visualized using a Nuance multispectral imaging system (Nuance 
1P46, Cambridge Research and Instrumentation, Inc. Woburn, MA) mounted on a Zeiss Axio Imager Z1 microscope. Image 
files (200×) were captured and merged using the Axiovision 4.5 package (open program). For all cells, nuclei were stained blue 
with DAPI. Cells were stained with anti-human DEK antibody (1:100, columns 1 and 2) or similarly diluted isotype control anti-
body (column 3). Bound antibody was detected with goat anti-mouse IgG (H+L) conjugated to Alexa Fluor 555. Row (A) 
shows the merged DAPI and Alexa Fluor 555 image, and row (B) shows the staining of the Alexa Fluor 555 image alone. Data 
is representative of more than three separate experiments.
                       AGN2a/DEK              AGN2a                AGN2a/DEK (control)
A
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the weekly vaccinations when testing for cell-mediated
anti-tumor immunity (Johnson, B.D., et al., 2007. CD25+
Regulatory T Cell Inhibition Enhances Vaccine-induced Immu-
nity to Neuroblastoma, J. Immunother., in press). Based on
this finding we used a single round of PC61 treatment in
the studies presented here.
We have used serum from mice immunized twice weekly
in the context of Treg-depletion to carry out a SEREX anal-
ysis, reasoning that unique neuroblastoma antigens may
be uncovered in vaccinated, as opposed to tumor-bearing,
animals. When an AGN2a cDNA library we prepared was
screened for the ability to express IgG-reactive antigens, a
number of transformation-associated proteins were iden-
tified, Table 1. These antigens were over-expressed in two
other murine neuroblastoma cell lines as well, when com-
pared to normal tissues, Figure 1, demonstrating that
immunization in the context of Treg inhibition can iden-
tify unique and potentially important transcripts. What
was most striking about our data was the abundant
number of "hits" that were generated against the DEK
oncogene. DEK was indeed over-expressed in neuroblast-
oma cell lines, Figure 1, and was recognized by immune
serum in ELISAs, Figure 5. Our SEREX analysis also iden-
tified some antigens that were not over-expressed in neu-
roblastoma, yet these antigens still induced an antibody
response. This response may either be due to the genera-
tion of cross-reactive antibody, or the antigens may be tar-
gets of an induced autoimmune response. It is also
possible that point mutations in these antigens may have
generated an immune response to them. Direct sequence
analysis of these proteins will be required to confirm or
refute this possibility and will be explored in future stud-
ies.
The combination of Treg depletion and vaccination may
also induce CD8 effector cells. Recent descriptions of
auto-reactive CD4 T cells that have expanded in vitro
upon Treg depletion from healthy individuals including
those specific for NY-ESO-1, tyrosinase, and GAD65 (a
type 1 diabetes-associated autoantigen) support this
hypothesis and suggest that Treg modulation may be
essential for inducing anti-tumor immunity [20,21].
ELISA Analysis of Immune Sera for DEK Reactivity Figure 5
ELISA Analysis of Immune Sera for DEK Reactivity. 96-well plates were coated with recombinant DEK or EGFP (10 μg/ml) pro-
duced in bacterial vectors. Wells were blocked, and 100 μl of test serum (as described on the x-axis), diluted 1:100, was added 
to each well. Sera used for this assay was the same serum used for cDNA library screening, and was pooled from 5 immunized 
mice. Serum from naïve A/J mice, mice treated with PC61 alone, or AGN2a-CD80/CD86 vaccine alone was derived from par-
allel experimental groups used in the immunization protocol. Following incubation at 37°C for 1 hour, secondary rabbit anti-
mouse IgG (H+L) was used to detect bound antibody, as detailed in Methods. Also included was anti-human DEK monoclonal 
antibody (Anti-DEK-MAb) used at 0.5 μg/ml. Error bars show standard deviations for triplicate sample wells in the same assay.
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IFN-γ ELISPOT Analysis of CD8 T cells from Immunized Mice Figure 6
IFN-γ ELISPOT Analysis of CD8 T cells from Immunized Mice. CD8 T cells from immunized and control mice were purified by 
immunomagnetic sorting and co-incubated with the indicated APCs (protein-loaded PEC or tumor cells) for18 hours. A) 1 × 
105 syngeneic PEC loaded with buffer (no protein), recombinant EGFP, or recombinant DEK were co-cultured with 1 × 105 
CD8+ T cells from the following groups of mice: naïve (stripes), PC61 treated (gray), PC61 treated plus AGN2a-CD80/86 vac-
cinated (cultured in normal mouse serum (ms)), (white), and PC61 treated plus AGN2a-CD80/86 vaccinated (cultured in FBS), 
(black). B) 5 × 104 CD8 T cells purified from naïve mice, PC61-treated mice, or AGN2a-CD80/86+PC61 treated mice were 
co-cultured with 1 × 104 tumor cells: AGN2a (white), AGN2a/pcDNA3.1 (gray, vector only control), AGN2a/DEK (stripes), or 
cultured alone (black, T cells only control). Data is representative of three separate experiments. Each experiment consisted of 
T cells purified and pooled from 5 mice. Error bars represent the standard deviation calculated from triplicate ELISPOT wells.
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The identification of DEK as a tumor-associated antigen in
murine neuroblastoma cell lines is fascinating due to the
expression of DEK in an expanding number of human
cancers. Both DEK and E2F3 have been identified as over-
expressed transcripts due to chromosome 6p gains in
retinoblastoma, a common pediatric malignancy [22].
Genomic gains of oncogenes like DEK are likely to be
selected for because they confer a growth advantage to the
malignancy, and 6p gains have been described in a
number of malignancies including bladder and gastro-
esophageal cancer, osteosarcoma, and melanoma [23-26].
DEK was first identified as part of a fusion protein with the
CAN/NUP 214 nucleoprotein in an acute myeloid leuke-
mia, AML, sub-type through an "in-frame" translocation
of chromosome 6 and 9 [27]. Biochemically, DEK is
known to regulate transcription and contains a DNA
binding domain, several phosphorylation sites, and a
SAF-Box (scaffold attachment factor). DNA binding is
dependent on phosphorylation by casein kinase 2 (CK2)
which appears to regulate its transcriptional regulatory
function [28-30]. Of note, we also identified CK2 by
immune serum-SEREX, Table 1. Most recently DEK was
demonstrated to reside in the spliceosome, and that upon
phosphorylation, DEK associates with U2AF, enforcing 3'
splice site discrimination, preventing U2AF from binding
to pyridine tracts not followed by AG sequence [31]. The
association with DEK over-expression or inactivation with
human disease may be related to alterations in splice-site
recognition and intron removal [32]. Evidence that DEK
regulates key genomic responses to DNA damage was
demonstrated by the ability of a partial fragment of DEK,
isolated by a cDNA library screen, to complement an
ataxia-telangiectasia phenotype in vitro [33]. In our
immune-SEREX screen we identified partial transcripts as
well, generated from an internal ATG sequence, that were
recognized by immune sera (not shown). The association
of DEK with cellular transformation has left little doubt of
its oncogenic potential. DEK has been shown to inhibit
senescence in cells infected with high-risk papillomavirus
and to associate with the latency protein LANA-1
expressed by KSHV (Kaposi's sarcoma-associated herpes-
virus) [34,35]. In the AML subset containing the
t(6;9)(p23;q34) chromosomal abnormality, monitoring
of the DEK-CAN transcript by RT-PCR shows an exact cor-
relation to therapeutic outcome [36].
DEK is a nuclear protein, and antibody responses to DEK
have been proposed to be indicators of autoimmune dis-
ease. However, in a report by Dong et al., it was proposed
that anti-DEK antibodies are not a marker for any specific
disease, but a marker for a subset of autoimmunity associ-
ated with IFN-γ production [37]. This is fascinating, as the
breaking of tolerance to a self/tumor-associated antigen,
as demonstrated by an IFN-γ mediated immune response,
is a key characteristic of generating Th1 immunity. Further
evidence for the ability to generate an immune response
specific for DEK was seen when a human CD4 T cell clone
specific to the DEK-CAN fusion protein produced IFN-γ
upon co-culture with dendritic cells loaded with either
apoptotic or necrotic t(6;9) leukemia cells [38]. Another
potential mechanism for the induction of an immune
response to self-proteins is the production of a truncated
transcript by the tumor itself. Immune responses to a
truncated HER-2/neu protein are far greater than to native
protein and have become a new focus for vaccine develop-
ment [39]. Although full-length recombinant DEK was
used throughout our studies, the isolation of a partial
transcript from the AGN2a cDNA library leaves this a pos-
sibility in our in vivo vaccine studies.
SEREX-based analysis of human cancers is entering a new
phase of development. Studies from the laboratory of Dr.
L. Old are beginning to describe how in different clinical
situations, it is the SEREX-identified antibody targets that
define discrete sets of over-expressed protein antigens that
predict tumor pathophysiology. Notably, their current
hypothesis is that SEREX specifically identifies tumor/self
antigens that are recognized by CD4+CD25+ regulatory T
cells, and that without induction of an inflammatory
immune response that includes CTL activity, immuniza-
tion with SEREX-identified antigens alone may actually
enhance tumor progression [40,41]. Our approach avoids
this concern, in that tumor antigens we identify in the
context of cell-based vaccination and Treg inhibition
occur in a physiological environment where protective
cytolytic T cell responses are being induced by the tumor
cell-based vaccine [8]. We anticipate testing our hypothe-
sis in human subjects immediately after the initial course
of chemotherapy, where tumor antigen has been newly
loaded in to the antigen-presenting cells, or following spe-
cific immunotherapeutic trials.
Conclusion
We have presented a new rationale for tumor antigen
identification using serum from mice vaccinated in the
context of altered tolerance, by blocking the function of
Treg cells. This procedure, which was developed for induc-
ing strong T cell responses, also generated a strong sero-
logical response. Few if any antigens were identified in
tumor-bearing, or Treg-blocked only animals. However,
vaccination in the context of Treg depletion produced
serum from which we were able to generate a candidate
tumor antigen list, and we demonstrate that for one of
these antigens, the DEK oncogene, a strong T cell response
is also induced. A number of these antigens are associated
with tumorigenicity and should be explored in their own
right. We conclude that tolerance mechanisms are opera-
tive in tumor-bearing animals, and that these may block
effective tumor antigen identification by serological
screening of cDNA libraries (SEREX). To extrapolate theseBMC Immunology 2007, 8:4 http://www.biomedcentral.com/1471-2172/8/4
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findings to human disease, serology-based antigen discov-
ery should be carried out not with onset or diagnostic
serum (which is most commonly banked), but with
serum derived from treated patients in which antigen
loading in to the immune system is optimal and in which
Treg effects may be minimized.
Methods
Mice and tumor cell lines
A/J mice, 6–8 weeks of age, were purchased from Jackson
Laboratories (Bar Harbor, ME). Mice were housed in the
Medical College of Wisconsin Biomedical Resource
Center (AALAC accredited) and all protocols were
approved by the MCW Institutional Animal Care and Use
Committee. AGN2a, an aggressive clone of Neuro2a, was
derived from successive in vivo passage, and AGN2a trans-
fectants that permanently express CD80 and CD86
(AGN2a-CD80/86) have been previously described [8].
Generation of immune serum
A/J mice were given two weekly subcutaneous (s.c.) injec-
tions of 2 × 106 irradiated AGN2a-CD80/86 cells. For
blockade/depletion of T-regulatory cells, mice received
500 μg of bioreactor generated (Integra CL 1000, Chur,
Switzerland) anti-CD25 monoclonal antibody (mAb),
clone PC61, by intraperitoneal (i.p.) injection 3 days prior
to the first vaccination. Blood was collected 5 days after
the second vaccination, incubated at 37°C for 30 min,
centrifuged at 800 × g for 10 min, and then stored at -
80°C.
Construction of cDNA expression libraries
Total RNA was isolated from AGN2a using Trizol (Invitro-
gen) according to the manufacturer's protocol and mRNA
purified using the Oligotex mRNA Kit (Qiagen). 5 μg of
purified poly-A mRNA was used to construct a cDNA
library using the ZAP Express cDNA Synthesis Kit and ZAP
Express cDNA Gigapack III Gold Cloning Kit (Stratagene,
Inc., La Jolla, CA). Three libraries based on size fractiona-
tion of packaged cDNA inserts were created. cDNA frag-
ments were cloned into the λZAPII Express Vector
(Stratagene), packaged into phage particles, and used to
transfect E. coli, resulting in at least 1.25 × 105 primary
recombinants per library. We screened the library with the
highest titer (2 × 107 pfu/ml) and the most representative
insert size species for mammalian mRNA (600–2500 bp
as determined by PAGE).
Immunoscreening of the AGN2a cDNA library
Proteins encoded by the cDNA expression library were
probed with sera from AGN2a-CD80/86+PC61 vacci-
nated mice (pooled from 5 mice). Recombinant phage at
a concentration of 5,000 pfu per plate (150 mm2) were
amplified for 4 hr at 42°C until plaques were visible and
then transferred to nitrocellulose membranes pre-wetted
with 10 mM IPTG (Invitrogen) for an additional 3.5 hr at
37°C. Membranes were then washed 3 times with TBST
(20 mM Tris-Cl, 150 mM NaCl, 0.05% Tween 20, pH7.5),
blocked with 1% bovine serum albumin (BSA, Sigma
A3803) in TBS, and then incubated with a 1:250 dilution
of immune serum, which had been pre-adsorbed with E.
coli phage lysate following the manufacturer's protocol
(Stratagene). Bound antibody was detected by incubation
with alkaline phosphatase-conjugated rabbit anti-mouse
IgG (H+L) (Abcam) and visualized by staining with 4-
nitro blue tetrazolium chloride/5-bromo-4-chloro-3-
indoyl-phosphate (NBT/BCIP, picoBLUE Immunoscreen-
ing Kit, Stratagene). Positive clones were subcloned and
re-screened as above. In vivo excision was carried out with
plaques that proved positive upon secondary screening in
order to generate the pBK-CMV phagemid containing the
cloned insert. Phagemid was isolated with QIAprep col-
umns (QIAGEN) and the size of the cDNA insert analyzed
by XhoI/EcoRI restriction digest. Inserts were sequenced
using T7 and T3 primers by automated DNA sequencing
(ABI 3100, MCW Protein and Nucleic Acid Facility). To
verify that phagemid-encoded cDNA was expressed by
AGN2a, newly generated cDNA (with Olido-dT and
SuperScript III, as above) was screened by PCR (34 cycles
at an annealing temperature of 55°C) using primers spe-
cific for each gene. Primers were designed on-line using
Primer3 [42].
Expression of DEK protein
Full-length DEK (GeneBank, BC055451) was cloned from
AGN2a cDNA using the following primers: (fwd) 5'-
GGAATTCCATATGCCGGGTCCCAGGGAAGAG, (rev) 5'-
CGGGATCCTCAAGAAATTAGCTCTTTTACAG. A small
portion of non-translated 5' sequence was included to
produce an in-frame product for protein expression and
to overcome the repetitive GC-rich region just prior to the
start codon. Primers used to amplify and clone EGFP
were: (fwd) 5'-CATATGGTGAGCAAGGGCGAG, (rev) 5'-
GGATCCGCTTTACTTGTACAGCT. NdeI and BamHI
restricted PCR fragments were ligated into pET-15b
(Novagen, Madison, WI) and recombinant plasmid insert
sequence (pET-15/DEK and pET-15/EGFP) was verified by
DNA sequencing. Plasmids were transformed into E. coli
strain BL21 (DE3) and gene expression induced with 0.8
mM isopropyl-β-D-thiogalactopyranoside (IPTG, Invitro-
gen). Prokaryotically-expressed proteins were purified
using a Ni-NTA Purification System (Invitrogen) and ana-
lyzed by SDS-PAGE and western blotting. Bacterial lysates
were lysed in reducing loading buffer (NuPAGE system,
Invitrogen), proteins resolved by SDS-PAGE, and the pro-
teins transferred to PVDF membranes (Invitrolon, 0.45
μm, Invitrogen) using a NuPAGE Bis-Tris electrophoresis
system (Invitrogen). Blots were probed with anti-human
DEK (BD Biosciences) and anti-His antibody (Serotec,
Raleigh, MC) at a 1:1000 dilution, followed by alkalineBMC Immunology 2007, 8:4 http://www.biomedcentral.com/1471-2172/8/4
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phosphatase conjugated rabbit anti-mouse IgG (H+L)
(Abcam) at a 1:2500 dilution. NBT/BCIP was used for AP
detection (picoBLUE Immunoscreening Kit, Stratagene).
To produce stable transfected cell lines, AGN2a was trans-
fected by electroporation with the pcDNA3.1-Hygro vec-
tor (Invitrogen) encoding DEK. Transfected cells were
selected by culture in 400 μg/ml hygromycin (Invitrogen),
cloned by limiting dilution, and subclones selected for
uniform DEK expression by immunofluorescent staining,
as follows: 1 × 105 cells were plated overnight in glass
chamber slides (Nalge, Nunc International), washed 2×
with PBS, and fixed with 4% paraformaldehyde (Sigma)
for 15 minutes at room temperature. The slides were
rinsed in PBS, blocked with 10% normal goat serum, and
then incubated overnight at 4°C with mouse anti-human
DEK (1:100, BD Biosciences) or isotype control (IgG1,
1:100, BD Biosciences). Slides were then rinsed in PBS
and then incubated for 1 hour with Alexa Fluor 555-con-
jugated goat anti-mouse IgG (H+L), (1:1000, Invitrogen).
After rinsing in PBS, the cells were incubated for 5 minutes
with 0.3 mM DAPI (Invitrogen) at room temperature.
Slides were mounted with Vectashield (Vector Laborato-
ries) and microscopically inspected.
Western blot analysis
AGN2a cells were washed twice with PBS, resuspended in
PBS at 5 × 106/ml, and diluted in three volumes 4× sample
buffer (NuPAGE LDS Sample Buffer, Invitrogen, Inc.). (A)
Lane 1, molecular weight (mw) marker and lanes 2
through 5, boiled AGN2a cell lysate (5 × 104 cell/well).
After resolution of proteins by SDS-PAGE (12%, NuPAGE
gel system, Invitrogen, Inc.), proteins were transferred to
PVDF membrane using a Bis-Tris electrophoresis buffer
system and transferred to Invitrolon PVDF membrane (as
above), then cut into strips. Lanes were blocked by incu-
bation for 1 hr at room temperature in 5% non-fat dry
milk and 1% BSA in Tris-buffered saline, pH 7.5, rinsed
and then incubated in: Lane 2, serum from naïve mice;
Lane 3, serum from PC61 treated mice; Lane 4, serum
from AGN2a-CD80/86 immunized mice; and Lane 5,
serum from AGN2a-CD80/86 immunized +PC61 treated
mice, diluted 1:100 in blocking buffer. Bound antibody
was detected with biotin-conjugated goat anti-mouse IgG
(Biotin-SP-conjugated AffiniPure Goat Anti-Mouse IgG,
Fcγ Fragment Specific, Jackson ImmunoResearch Labora-
tories, Inc., West Grove, PA) diluted 1:1000 in blocking
buffer, washed, then incubated with AP labeled-ExtraAvi-
din (Extravidin-Alkaline Phosphatase, Sigma) and
detected with picoBLUE as above. Data is representative of
more than three separate experiments. (B) Lane 1, molec-
ular weight marker; Lane 2, Coomassie blue stain of pro-
teins resolved by SDS-PAGE of the AGN2a cell lysate.
Vaccination and immune assays
A/J mice were immunized by subcutaneous (s.c.) injec-
tion of 2 × 106 irradiated (5000 rad) AGN2a-CD80/86
cells cultured in DMEM supplemented with 2% mouse
serum (Equitech-Bio) or 10% FBS (Gemini Bio-Products)
in the context of PC61 treatment (as above). Five days fol-
lowing the second of two weekly vaccinations, spleno-
cytes were collected, depleted of red cells, and CD8+ T cells
purified using the CD8a (Ly-2) Microbead kit (Miltenyi
Biotech) on an AutoMACS device (Miltenyi Biotech).
ELISPOT analysis to enumerate CD8+  IFN-γ-producing
cells was carried out using the BD ELISPOT mouse IFN-γ
Set and 96-well PVDF membrane plates (Millipore, Bed-
ford, MA) according to the manufacturer's protocols. In
some assays, peritoneal exudate cells (PEC) were used as
antigen-presenting cells. 1 × 105 PEC from naïve A/J mice
were placed in ELISPOT wells and loaded with protein by
incubating in 100 μl media containing recombinant DEK
or EGFP at 25 μg/ml for 4 hours at 37°C. 1 × 105 CD8+ T
cells (in 100 μl) were added to each well for 18 hr to test
for antigen recognition. For direct recognition of tumor
cells, 1 × 104 neuroblastoma cells (AN2a or AGN2a/DEK)
were incubated with 5 × 104 CD8+ T cells. Spots were
counted using an automated reader (Immunospot 3,
C.T.L., Ltd., Cleveland, OH).
DEK-specific IgG was detected by coating 96-well plates
(EIA/RIA, Costar, Corning, NY) with bacterially-expressed
DEK or EGFP (1 μg per well) in carbonate buffer (45.3
mM NaHCO3, 18.2 mM Na2CO3, pH 9.6). Diluted sera
was added to blocked wells and detected with rabbit anti-
mouse IgG (H+L) labeled with alkaline phosphatase
(Abcam) and developed with NNBT/BCIP (Stratagene).
Microarray analysis
The normal mouse tissues (brain, heart, lung, rib cage,
spleen, liver and kidney) and tumors established using
TBJ and Neuro-2a murine neuroblastoma cell lines were
used for microarray analysis. For each tissue or tumor, at
least two samples were used. Total RNA was purified using
a combination of Trizol extraction followed by Qiagen
column purification [43]. We utilized mouse cDNA
microarray chips consisting of 19940 probes representing
13,958 non-redundant genes in a cDNA microarray exper-
iment carried out precisely as previously described [43].
NIH3T3 RNA was used as reference in all hybridizations.
To investigate the expression of SEREX identified tran-
scripts in different mouse tissues and neuroblastoma cell
lines, we used UGRepAcc to match the SEREX identified
genes and the genes existing in cDNA array, 22 of 25
SEREX-identified genes having matches. In the case of
multiple clones representing the same gene, the average of
expression ratio was used. The data were log2 transformed
and z-score normalization was performed across samples
for each gene. Hierarchical clustering analysis was per-BMC Immunology 2007, 8:4 http://www.biomedcentral.com/1471-2172/8/4
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formed using the Pearson distance as the distance meas-
ure.
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